Tonix Pharmaceuticals Develops TNX-801 Vaccine for Monkeypox and Smallpox
Tonix Pharmaceuticals showcases new data on TNX-801 vaccine demonstrating reduced virulence compared to traditional vaccines and protection against monkeypox. Learn more about the company's efforts in advancing vaccine development and its potential impact on global health.
This news highlights the innovative efforts of Tonix Pharmaceuticals in developing a vaccine with the potential to provide durable protection against monkeypox and smallpox outbreaks. The development of TNX-801 could have significant implications for public health and global disease prevention strategies.
